Abstract:
Methods and microorganisms for forming fermentation products utilizing a microorganism having at least one heterologous gene sequence that enables carbohydrate conversion and carbon dioxide fixation in the production of the fermentation products are disclosed according to some aspects.
Abstract:
The present invention encompasses isolated gene regulatory elements and gene transcription terminators that are differentially expressed in a native fungus exhibiting a first morphology relative to the native fungus exhibiting a second morphology. The invention also encompasses a method of utilizing a fungus for protein or chemical production. A transformed fungus is produced by transforming a fungus with a recombinant polynucleotide molecule. The recombinant polynucleotide molecule contains an isolated polynucleotide sequence linked operably to another molecule comprising a coding region of a gene of interest. The gene regulatory element and gene transcription terminator may temporally and spatially regulate expression of particular genes for optimum production of compounds of interest in a transgenic fungus.
Abstract:
Provided herein are fungi, such as Aspergillus niger, having a dolichyl-P- Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase (Alg3) gene genetic inactivation, increased expression of a loss of aflR expression A (Lae), or both. In some examples, such mutants have several phenotypes, including an increased production of citric acid relative to the parental strain. Methods of using the disclosed fungi to make citric acid are also provided, as are compositions and kits including the disclosed fungi.
Abstract:
The production of hEGF is achieved in both whole plants and plant cell culture wherein the hEGF has a length of at least 200 amino acids. For epidermal growth factor this would comprise at least a tetramer of EGF units. Effectiveness or production of the translation process has been increased according to the present invention by (1) cloning of pre-pro-EGF cDNA of approximately 4.5 kb into both whole plants and cell culture to increase overall titers of active hEGF; (2) synthesizing cDNA and transforming plants and cell culture for production of an oligomeric polypeptide consisting of repeated hEGF domains; and (3) increasing the overall size of the gene to be expressed with a fusion construct encoding hEGF linked to a protein that is efficiently produced in plant systems. As needed, synthetic cDNA includes plant-specific proteolytic cleavage sites between EGF repeats to facilitate correct processing in planta. Appropriate proteolytic cleavage sites upstream and downstream of hEGF are added if needed to obtain final product. In whole plants, use of a regulatory element confers hEGF production characteristics into traditionally non-saleable portions of crop plants, such as the leafy tops of potatoes. Use of potato tops under post-harvest conditions, results in overexpression production of hEGF in non-saleable plant portions towards the end of the harvesting season, without affecting crop quality.
Abstract:
Fungi, such as Aspergillus niger , having a dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase ( Alg3 ) gene genetic inactivation, increased expression of a loss of afl R expression A ( LaeA ), or both, are described. In some examples, such mutants have several phenotypes, including an increased production of citric acid relative to the parental strain. Methods of using the disclosed fungi to make citric acid are also described, as are compositions and kits including the disclosed fungi. Further described are Aspergillus terreus fungi overexpressing the LaeA gene and the use of such fungi for the production of itaconic acid. In some instances, the A. terreus fungi also include a genetic inactivation of the Alg3 gene.
Abstract:
The invention includes methods for production of a polypeptide having factor VIII activity by introduction of a polynucleotide construct into a plant cell. The construct includes an encoding sequence for a polypeptide of coagulation factor VIII or a functional variant thereof. The plant cell is cultured or regenerated into a plant and the polypeptide or functional variant of factor VIII is expressed therein. The invention also includes vectors, plant cells, plant tissues, plants and seeds containing a polynucleotide sequence encoding a functional variant of human coagulation factor VIII. The invention further includes a recombinant DNA molecule having a promoter which is functional in plants operably linked to a coding sequence which codes for a polynucleotide having coagulation factor VIII activity.
Abstract:
Provided herein are fungi, such as Aspergillus niger, having a dolichyl-P- Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase (Alg3) gene genetic inactivation, increased expression of a loss of aflR expression A (Lae), or both. In some examples, such mutants have several phenotypes, including an increased production of citric acid relative to the parental strain. Methods of using the disclosed fungi to make citric acid are also provided, as are compositions and kits including the disclosed fungi.
Abstract:
An integrated system for commerical production of a heterologous protein in transgenic plants under conditions of controlled environment agriculture (CEA) is provided. CEA comprises growth of plants under defined environmental conditions, preferably in a greenhouse, to optimize growth of the transgenic plant as well as expression of the gene encoding the heterologous protein. The transgenic plants used in the present invention are transformed with an expression vector comprising a CEA promoter operably linked to a gene encoding the heterologous protein of interest, wherein the CEA promoter is selected to maximize heterologous protein production under the defined environmental conditions of CEA.
Abstract:
A composition is provided for transgenic plants and transgenic plant derived human coagulation factors capable of eliciting an activation response in human blood clotting pathways and therefore useful for the treatment of human beings diagnosed to be deficient in blood clotting factor proteins. Such proteins may be manufactured by methods resulting in viral free production using both whole plants and plant cell cultures. Also provided are expression vectors for the proper transformation of plant tissue for the production of such factors, as well as transformed plant cells and processes for producing human coagulation factors using plant molecular biology techniques.